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OBJECTIVES We sought to examine trends in the use and outcomes of transmyocardial revascularization
(TMR) in community practice. We also identified important risk factors for TMR and
compared outcomes of TMR combined with coronary artery bypass graft surgery (TMR 
CABG) versus bypass alone in patients receiving incomplete revascularization.
BACKGROUND Although it is approved for use as a stand-alone procedure, there are limited data on the
outcomes of (TMR  CABG).
METHODS We identified 3,717 patients receiving TMR at 173 U.S. hospitals participating in the Society
of Thoracic Surgeons (STS) National Cardiac Database. Baseline characteristics and
outcomes in these patients were compared with those from six published randomized TMR
trials. Multivariable logistic regression was used to identify clinical risk factors for mortality
with TMR. Risk-adjusted mortality was also compared for TMR  CABG relative to
CABG only in patients not amenable to complete traditional revascularization.
RESULTS Between January 1998 and December 2001, the number of STS hospitals performing TMR
and total procedural counts increased markedly, driven predominately by more TMR 
CABG cases. Overall mortality rates for TMR-alone and TMR  CABG were 6.4% and
4.2%, respectively. Operative risks were significantly higher in those patients with recent
myocardial infarction, unstable angina, and depressed ventricular function. Among patients
receiving incomplete revascularization, TMR  CABG was not associated with decreased
mortality risk compared with CABG alone, adjusted odds ratio 1.11 (95% confidence interval
0.74 to 1.67).
CONCLUSIONS The use of TMR, and in particular, TMR  CABG, is expanding in community practice.
Although procedural risks are high, there is room for optimization through improved patient
selection and timing of the procedure. Further studies of TMR  CABG are needed given
its growing use and unclear benefits. (J Am Coll Cardiol 2003;42:1611–6) © 2003 by the
American College of Cardiology Foundation
Transmyocardial revascularization (TMR) is a recently de-
veloped alternative treatment for patients with advanced
coronary disease whose anatomy is not amenable to percu-
taneous coronary intervention or conventional coronary
artery bypass graft surgery (CABG). During TMR, small
“channels” or holes are created in the heart via a laser device
applied to the myocardial surface. This procedure can be
performed as sole therapy (TMR-only) or in combination
with bypass surgery (TMR  CABG). Although the
mechanism(s) by which TMR may work remain unclear
(1–7), each of six small randomized studies demonstrated
that TMR-only significantly reduced angina symptoms
relative to continued medical care, but did not reduce acute
or long-term mortality (8–13). An additional randomized
trial compared TMR  CABG versus CABG alone in
patients not amenable to complete revascularization. This
trial could not demonstrate an incremental benefit of TMR
on anginal status, yet it did report lower operative mortality
with the combined procedure than CABG alone (14).
Although these randomized trials demonstrated the po-
tential benefits of TMR, they also documented the proce-
dure’s risks. Overall procedural mortality rates in these trials
ranged from 1% to 5%. The TMR risks were particularly
high among patients with unstable angina, recent cardiac
events, or depressed left ventricular function (9,10). Weigh-
ing the risks and benefits of TMR-only, the Food and Drug
Administration (FDA) gave market approval for its use in
patients with stable angina refractory to medical therapy and
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lacking traditional revascularization options. This approval
for TMR-only, however, came with a requirement for the
laser’s manufacturers to undertake large post-marketing
safety studies. Given a paucity of information, manufactur-
ers have not yet sought an FDA indication for TMR 
CABG, and its use in practice remains “off-label.”
In addition to these manufacturers’ studies, the FDA, in
collaboration with the Society of Thoracic Surgeons (STS)
and the Duke Clinical Research Institute (DCRI), initiated
an independent evaluation of the use and safety of TMR in
community practice. This study reviews trends in the use of
TMR-only and TMR  CABG between 1998 and 2002
among more than 400 hospitals participating in the STS
National Cardiac Database. We also examined the acute
operative mortality and major morbidity following TMR
and determined how these risks varied as a function of
patient characteristics. Finally, we investigated whether
TMR  CABG was associated with fewer procedural
complications relative to traditional CABG in patients not
amenable to complete revascularization.
METHODS
Data. Clinical data for the STS Database were collected
using methods described more fully elsewhere (15). Briefly,
the database was developed in 1990 as a multicenter clinical
repository for quality improvement and clinical research.
The STS Database collects data from approximately two-
thirds of all U.S. cardiothoracic hospitals and contains
detailed data on patient demographics, clinical profile, and
acute outcomes on more than 2.1 million procedures. Data
definitions are standardized and site data coordinators
receive initial and ongoing training in these definitions.
Sites voluntarily submit data to the data coordinating center
(DCRI) on a semi-annual basis and receive site-specific
feedback, bench-marked against regional and national re-
sults. Accuracy of individual data elements have been
validated in regional analyses, and overall completeness of
mortality event reporting in patients age 65 years or older
has been validated against national Medicare claims files
(16).
Patient population. The study population consisted of all
patients in the STS Database receiving TMR between
January 1998 and December 2001. Procedures were further
subdivided as TMR-only, TMR  CABG, or TMR-other
(TMR used in conjunction with other surgical procedures
such as valve surgery or ventricular-septal defect repair). The
TMR-other cases were included in the trend analysis, but
excluded from the outcomes analyses given their higher
procedural risks.
Literature search. A literature search was conducted to
identify TMR clinical trials published between 1995 and
2001. This search was supplemented by reviewing study
bibliographies and review articles, and direct discussions
with all study lead authors. Studies were included if they
randomized patients to receive TMR (alone or combined
with other procedures). Percutaneous myocardial revascu-
larization studies were not included.
Statistical analysis. Categorical variables were presented as
percentages whereas continuous variables are presented as
median and interquartile ranges unless otherwise stated.
Chi-square and Kruskall-Wallis tests were used to compare
characteristics across groups of patients for categorical and
continuous variables, respectively.
The primary outcome of interest was operative mortality,
defined as any in-hospital death or death within 30 days of
the procedure. In addition, morbidity end points examined
included reoperation for any reason, deep sternal wound
infection, renal failure, prolonged ventilation, or permanent
stroke. Outcomes of TMR in the STS database were
compared by procedure type to those seen in the random-
ized TMR trials. Five of the six TMR trials (8–12) provided
complete 30-day mortality results. These outcomes were
summated as a random effect estimate using FASTPRO.
Logistic regression was used to identify univariate and
multivariate preoperative risk factors for mortality and
mortality/morbidity outcomes following TMR. Candidate
variables for this analysis came from known predictors of
bypass mortality (17) and from those identified from TMR
clinical trials. In later analyses, we added procedure type
(TMR-only vs. TMR  CABG), temporal trends in
outcomes (year of procedure), and TMR hospital volume
beyond our clinical factors to our multivariable models.
Finally, we compared the crude and risk-adjusted out-
comes of patients with triple-vessel coronary disease who
received one to two bypass grafts (that is, incomplete
revascularization) with those of similar patients receiving
TMR  CABG. These observational treatment compari-
sons were adjusted for 28 preoperative risk factors associated
with CABG mortality or mortality  morbidity (17).
RESULTS
Between January 1998 and December 2001, a total of 3,717
TMR procedures were performed at 173 (31%) of STS
National Cardiac Database sites. Of these procedures, 661
(17%) were TMR-only procedures, 2,475 (67%) were TMR
 CABG, and 581 (16%) were TMR in combination with
some other cardiac procedure. The overall number of sites
performing TMR increased from 33 (7% of total STS sites)
in 1998 to 131 (36% of sites) in 2001. Similarly, the annual
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volume of TMR procedures rose from 59 procedures in the
first half of 1998 to 572 in the second half of 2001, driven
predominately by the expansion in the use of TMR 
CABG. The volume of TMR procedures per site ranged
from 1 to 150 procedures during the study period, with a
median of 12 and an interquartile range of 4 to 27.
Comparison of patient characteristics and outcomes.
Table 1 provides a comparison of composite baseline patient
characteristics from patients enrolled in the randomized
TMR trials and those from the STS TMR population.
Overall, patients enrolled in the TMR trials had similar
demographic and clinical characteristics as those receiving
TMR in community practice. Patients receiving TMR had
a mean age ranging from 61 to 65 years. Women accounted
for one-third of all patients. Comparing the procedure
types, patients who underwent TMR  CABG in either
the trials or in STS tended to be slightly older, but were
markedly less likely to have prior bypass surgery relative to
those receiving TMR-only.
TMR outcomes. Table 2 provides STS TMR-only and
TMR  CABG mortality, morbidity and mortality or
major morbidity end points. The overall STS operative
mortality for TMR-only patients was 6.4% (95% confidence
interval [CI] 4.8 to 8.7). This tended to be higher than the
30-day mortality rates seen in the individual randomized
clinical trials (RCTs), ranging from 1.1% (95% CI 0.0 to
5.9) to 5.3% (95% CI 2.2 to 10.6) or composite average
mortality rate for the RCTs 3.5% (95% CI 1.8 to 5.2).
Similarly, mortality for the STS TMR  CABG patients
was 4.2% (95% CI 3.5% to 5.1%) versus a mortality rate of
1.5% (95% CI 0 to 3) in the single RCT of TMR CABG
(Fig. 1).
The most frequent TMR operative complication was
prolonged ventilatory support 24 h required by 7.7% and
9.1% of STS TMR-only and TMR  CABG patients,
respectively (Table 2). Renal failure also occurred in nearly
5% of both TMR-only and TMR  CABG patients.
The frequency of TMR postoperative mortality or com-
plications was significantly higher among older patients, in
diabetes, and in those patients with recent myocardial
infarction (MI) or unstable angina. In contrast, patient
gender and degree of underlying coronary disease severity
was not associated with increased operative risk. When used
in patients without recent MI, unstable angina, and an
ejection fraction of 30%, TMR-only (n  243 patients)
mortality rates declined to 3.7% and TMR  CABG (n 
1,067) fell to 2.6%.
Multivariable predictors of TMR risk. Figure 2 displays
the independent patient risk factors associated with TMR
operative mortality. Increasing age, diabetes, unstable an-
Table 1. Baseline Characteristics of Patients Enrolled in Randomized Trials and Those in the
STS National Database
Baseline Characteristics
TMR-Only 5 RCT
Composite
TMR 
CABG RCT
STS
TMR-Only TMR  CABG
Time period 1993–1998 1996–1997 1998–2001 1998–2001
Sample size (n) 722 263 661 2,475
Age (mean yrs  SD) 61 64  10 62  11 65  10
Female (%) 17 27 30 27
Hypertension (%) 62 n/a 76 76
Diabetes mellitus (%) 34 51 49 50
Hyperlipidemia (%) 67 n/a 74 68
Smoking history (%) 41 n/a 62 59
CCS class
III (%) 47 n/a 32 35
IV (%) 53 n/a 46 23
Family history (%) 59 n/a 45 43
Prior heart failure (%) 19 n/a 20 15
Prior MI (%) 68 43 53 50
LVEF (mean) 50 51  13 46  13 50  14
LVEF 45% (%) 47 n/a 42 37
Prior CABG (%) 76 20 87 28
Prior PTCA or CABG (%) 73 n/a 91 43
CABG  coronary artery bypass graft surgery; CCS  Canadian Cardiovascular Society; LVEF  left ventricular ejection
fraction; MI  myocardial infarction; PTCA  percutaneous transluminal coronary angioplasty; RCT  randomized clinical
trials; STS  Society of Thoracic Surgeons; TMR  transmyocardial revascularization.
Table 2. STS TMR Outcomes by Procedure Type
Procedure Outcome
TMR-Only
n  661
TMR  CABG
n  2,475
Mortality
In-hospital 5.9 4.0
In-hospital or 30-day 6.4 4.2
Morbidity
Any re-operation 2.7% 6.6%
Prolonged ventilation (24 h) 7.7% 9.1%
Renal failure 4.8% 4.8%
Stroke 0.8% 1.9%
Deep sternal wound infection 0.3% 0.7%
Operative mortality or
morbidity*
14.8% 17.2%
*Includes operative mortality, reoperation for any reason, deep sternal wound
infection, renal failure, prolonged ventilation, or permanent stroke.
Abbreviations as in Table 1.
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gina, peripheral vascular disease, prior CABG, lower ejec-
tion fraction, and MI within 21 days of procedure were
independently associated with an increased risk of operative
mortality. The C-index for this multivariable model was
0.75.
After adjusting for baseline clinical risk, neither patient
gender nor procedure type (TMR-only versus TMR 
CABG) was associated with increased procedural mortality.
Additionally, there were no significant temporal trends in
risk-adjusted TMR outcomes over the four years of study (p
 0.31). In contrast, there was a trend towards better TMR
outcomes with increasing procedural volume. Low TMR
volume sites (1 to 6 procedures) had a mortality rate of
6.2%, versus 4.6% among intermediate sites (7 to 18
procedures) and 4.3% among high-volume sites (18 pro-
cedures) (p  0.09 for trend).
Comparison of TMR  CABG versus CABG-only. A
total of 39,454 STS CABG patients had triple-vessel
coronary disease, but received 3 bypass grafts, presumably
because of technical inability to graft those regions of the
myocardium. Of these patients, 390 underwent a combined
TMR  CABG procedure. Compared with CABG-only
patients, patients who underwent TMR  CABG had
similar to higher unadjusted incidence of acute adverse
events (mortality: 4.9% vs. 4.1%, p  0.37; mortality/
morbidity: 18.1% vs. 15.5%, p  0.09). TMR  CABG
was also not associated with lower operative risk after
adjusting baseline clinical factors; adjusted TMR  CABG
OR for mortality  1.11 (95% CI 0.74 to 1.67) and for
mortality and morbidity 1.13 (95% CI 0.89 to 1.42).
DISCUSSION
To date, this study is the largest to evaluate TMR use and
outcomes. Using the STS National Cardiac Database, we
found that the adoption of TMR into U.S. clinical practice
has been rapid, with nearly a one-third of centers adopting
the procedure within a four-year period. The rise in the
procedure’s popularity has been driven predominately by
increased use of TMR  CABG, an off-label application of
the technology. Finally, the operative risks of TMR-only
and TMR  CABG in community practice remain higher
than those seen with traditional revascularization proce-
dures.
The application of TMR into clinical practice has been
rapid and potentially driven by multiple factors. First, TMR
represents one of the few existing treatment options for
patients with medically refractory angina who are not
candidates for traditional revascularization. In these pa-
tients, randomized (but unblinded) clinical trials have dem-
onstrated that TMR provided angina relief relative to
medical therapy. Finally, TMR requires little additional
technical training and commands professional fees similar to
those provided for traditional bypass surgery.
The current large series provides clinicians and patients
with estimates of mortality and morbidity associated with
TMR procedures in contemporary community practice. We
found that the operative mortality and morbidity risk of
TMR tended to be higher than those seen in prior random-
ized trial populations. These results are similar to those seen
in another international TMR registry (18). These higher
risks in community practice may be due to the use of TMR
in a less select patient population outside of clinical trials
and/or the differential provider effects outside of specialized
medical centers. The impact of the latter is suggested by a
trend towards lower risks at centers performing higher
annual TMR caseloads.
Our study also clearly demonstrates that operative risks
Figure 1. Thirty-day transmyocardial revascularization (TMR) mortality
rates from clinical trials and from the Society of Thoracic Surgeons (STS)
registry database. An overall combined rate (assuming random effects) of
clinical trials results is provided for descriptive purposes only. CABG 
coronary artery bypass graft surgery; RCT  randomized clinical trial.
Figure 2. Independent predictors of operative mortality following
transmyocardial revascularization (TMR) from the Society of Thoracic
Surgeons (STS) database. CABG  coronary artery bypass graft surgery;
CI  confidence interval; EF  ejection fraction; MI  myocardial
infarction; OR  odds ratio; PVD  peripheral vascular disease.
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for TMR vary markedly as a function of specific patient
subgroups (Table 3, Fig. 2). These identified risk factors as
similar to those found in prior studies (19,20). However,
despite these prior works, our study found that many
received TMR in community practice under less than ideal
conditions. For example, up to 50% of those receiving TMR
were classified as having unstable angina and up to a
one-quarter had an MI within 21 days of their TMR
procedure. Patients with these unstable symptoms had
mortality rates nearly twice as high as those without. On the
other hand, among patients with a stable clinical course and
preserved ejection fraction (30%), the procedural risk of
TMR-only and TMR  CABG mortality risks was nearly
halved. These findings emphasize the need to improve
algorithms for TMR patient selection and timing of proce-
dures.
Beyond these risk factors, the size of the STS registry
allowed us a unique opportunity to explore the outcomes of
TMR in women. Fewer than 200 women had been enrolled
in the six prior clinical trials combined. In our registry of
nearly 1,000 women receiving TMR, we did not find
evidence for gender-specific risks for mortality or major
morbidity following TMR.
Importantly, our study revealed that TMR  CABG
accounted for the majority of procedures currently per-
formed, yet there is limited information regarding the safety
and efficacy of TMR in this setting. In a single randomized
study of 266 patients not amenable to complete revascular-
ization, Allen and colleagues reported that TMR  CABG
significantly reduced in-hospital mortality rates relative to
CABG only (1.5% vs. 7.6%, p 0.02) (14). Although these
results were promising, observational comparison of TMR
 CABG in a single institution study (n  169) and in our
larger STS analysis failed to confirm these acute survival
benefits (Table 4).
Study limitations. Although we used this study to address
national trends in TMR use and outcomes, our data were
limited to those available in the STS database. However,
this data source represents nearly two-thirds of U.S. oper-
ative centers. Second, there are currently two laser devices
approved by the FDA for the TMR procedure: the CO2
laser and the Ho:YAG laser. As the STS Database does not
Table 3. STS TMR Outcomes by Patient Subgroups
Subgroup N
Operative Mortality Mortality or Major Morbidity*
TMR-Only
(%)
TMR  CABG
(%)
TMR-Only
(%)
TMR  CABG
(%)
Age
75 yrs 2,641 5.4 3.5 13.4 16.1
75 yrs 495 12.6 7.4 24.1 22.8
Gender
Men 2,259 6.9 4.3 15.8 17.0
Women 877 5.1 3.7 12.8 17.8
Diabetes
Nondiabetics 1,588 3.8 3.8 12.1 15.7
Diabetics 1,548 9.0 4.6 17.8 18.7
Previous MI
No Prior MI 1,536 2.6 3.3 9.4 16.1
MI 21 days 1,130 9.2 4.2 19.3 16.9
MI 21 days 470 13.0 6.6 21.7 21.0
Angina
Stable 1,570 4.3 2.8 10.8 15.3
Unstable 1,566 8.3 5.5 18.6 19.1
Diseased vessels
2 vessels 861 6.5 4.2 15.0 15.3
3 vessels 2,275 6.3 4.1 14.7 17.8
*Includes operative mortality, reoperation for any reason, deep sternal wound infection, renal failure, prolonged ventilation, or
permanent stroke. p  0.001 for comparison of mortality and mortality/morbidity among age groups, diabetes status, MI status,
unstable angina status for both TMR only and for TMR  CABG. p  0.1 for comparisons of gender and diseased vessels
outcomes.
Abbreviations as in Table 1.
Table 4. Outcomes Among Patients With Three-Vessel Disease Receiving Two or Fewer
Bypass Grafts With or Without TMR in STS
Outcome CABG-Only
TMR 
CABG
Unadjusted OR
(95% CI)
Adjusted OR
(95% CI)
Operative mortality (%) 4.1 4.9 1.19 (0.81–1.76) 1.11 (0.74–1.67)
Operative mortality  major morbidity* 15.5 18.1 1.20 (0.97–1.50) 1.13 (0.89–1.42)
*Includes operative mortality, reoperation for any reason, deep sternal wound infection, renal failure, prolonged ventilation, and
permanent stroke.
CI  confidence interval; OR  odds ratio. Other abbreviations as in Table 1.
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collect device-specific results, we cannot comment on
whether results differ by TMR device type. Third, partici-
pation in the STS Database is voluntary without full
external clinical event validation. Any under-reporting of
events would make our risk estimates conservative. Finally,
our database was observational and comparisons of specific
treatments, even when risk-adjusted, represent hypothesis
generation rather than hypothesis testing.
Clinical implications. The STS National Database offered
a prime opportunity to track use and results of a new
technology in the “real world.” Our finding of the wide-
spread use of TMR  CABG indicates a strong need for
further studies of this procedure. Additionally, our study
allows for the estimation of patient-specific risks with
TMR. Understanding these risks is key to the informed
decision process. Although prior randomized trials have
demonstrated the symptomatic benefits from TMR, these
must be weighted against the upfront procedural risks.
Finally, the results of this study point out the potential for
a reduction in TMR morbidity and mortality through
optimization of the timing of the procedure. Up to one in
two patients currently receiving TMR have the procedure
following a recent cardiac event or had unstable symptoms.
As previously published studies and the current study
document the relatively adverse events associated with
TMR in these settings, we believe that these refinements in
timing of TMR can lower the procedure’s risks.
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